Private Advisor Group’s Intellia Therapeutics NTLA Stock Holding History

Private Advisor Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,473	Closed	-$325K	–	2206
2022 Q1	$325K	Sell	4,473 -4,177	-48%	-$354K	﹤0.01%	1634
2021 Q4	$1.02M	Sell	8,650 -6,702	-44%	-$840K	0.01%	1112
2021 Q3	$2.06M	Buy	15,352 +4,360	+40%	+$660K	0.01%	868
2021 Q2	$1.78M	Sell	10,992 -4,358	-28%	-$339K	0.02%	805
2021 Q1	$1.23M	Buy	15,350 +7,426	+94%	+$498K	0.01%	910
2020 Q4	$431K	Buy	+7,924	New	+$288K	﹤0.01%	1290
2020 Q3	–	Sell	-513	Closed	-$11K	–	2800
2020 Q2	$11K	Buy	+513	New	+$8.71K	﹤0.01%	2895

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Private Advisor Group's NTLA Position: Q2 2022 in Review

Private Advisor Group sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 4,473 shares — an estimated $325K sold.

Private Advisor Group first reported a position in NTLA in Q2 2020 and held it in 7 quarters. The position peaked at $2.06M in Q3 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Private Advisor Group reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Private Advisor Group sold 4,473 Intellia Therapeutics shares in Q2 2022, an estimated $325K.
Private Advisor Group first reported a position in Intellia Therapeutics in Q2 2020 and held it in 7 quarters.
Private Advisor Group's Intellia Therapeutics position peaked at $2.06M in Q3 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Private Advisor Group's 13F filing for Q2 2022, filed 13 Jul 2022.